This transcript has been edited for clarity.
Ileana L. Piña, MD, MPH: Hello. I'm Ileana Piña from Thomas Jefferson University in Philadelphia. I'm the quality chief. This is my blog today from the European Society of Cardiology (ESC) Congress in Barcelona. It's been an incredibly exciting meeting. Everyone is so happy to be together again in person, and you can really feel the energy in the rooms.
Giving to that energy has been the awaited presentation of DELIVER, the dapagliflozin in preserved function study. I've got Scott Solomon here, who is the primary investigator (PI) of the trial. Welcome. Scott is from the Brigham and Women's Hospital, and he's been working very hard.
Give us the overall view of the trial from your standpoint.
Scott D. Solomon, MD: I'm very excited, first of all, to have a chance to talk to you about this, Ileana. DELIVER, as you know, is the largest and most inclusive trial in heart failure with mildly reduced and preserved ejection fraction.
Piña: Both.
Solomon:Both. We enrolled patients with an ejection fraction above 40%, and we also included patients who had heart failure with improved ejection fraction, which is a group that had never really been studied before.
Cardiologists, Patients Can Talk Drug Costs
Early or Delayed AF Ablation After Heart Failure Hospitalization?
Skill Checkup: A 69-Year-Old Woman With Worsening Heart Failure and Iron Deficiency
COMMENTARY
DELIVERing the Details on Dapagliflozin in Heart Failure
Ileana L. Piña, MD, MPH; Scott D. Solomon, MD
DisclosuresSeptember 02, 2022
This transcript has been edited for clarity.
Ileana L. Piña, MD, MPH: Hello. I'm Ileana Piña from Thomas Jefferson University in Philadelphia. I'm the quality chief. This is my blog today from the European Society of Cardiology (ESC) Congress in Barcelona. It's been an incredibly exciting meeting. Everyone is so happy to be together again in person, and you can really feel the energy in the rooms.
Giving to that energy has been the awaited presentation of DELIVER, the dapagliflozin in preserved function study. I've got Scott Solomon here, who is the primary investigator (PI) of the trial. Welcome. Scott is from the Brigham and Women's Hospital, and he's been working very hard.
Give us the overall view of the trial from your standpoint.
Scott D. Solomon, MD: I'm very excited, first of all, to have a chance to talk to you about this, Ileana. DELIVER, as you know, is the largest and most inclusive trial in heart failure with mildly reduced and preserved ejection fraction.
Piña: Both.
Solomon:Both. We enrolled patients with an ejection fraction above 40%, and we also included patients who had heart failure with improved ejection fraction, which is a group that had never really been studied before.
© 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ileana L. Piña, Scott D. Solomon. DELIVERing the Details on Dapagliflozin in Heart Failure - Medscape - Sep 02, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Ileana L. Piña, MD, MPH
Professor of Medicine/Cardiology/Heart Failure/Transplant; Quality Officer, Cardiovascular Line, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania; Clinical Professor of Medicine, Central Michigan University College of Medicine, Mount Pleasant, Michigan; Adjunct Professor of Epidemiology and Biostatistics, Population and Quantitative Health Sciences, Case Western University, Cleveland, Ohio
Disclosure: Ileana L. Piña, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, office, partner, employee, advisor, consultant, or trustee for: US Food and Drug Administration; Center for Devices and Radiological Health
Scott D. Solomon, MD
Director, Clinical Trials Outcomes Center, Brigham and Women's Hospital; Professor, Chair, Department of Cardiovascular Medicine, Harvard Medical School, Boston, Massachusetts
Disclosure: Scott D. Solomon, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Abbott Vascular; Action Medical Research; Akros; Alnylam Pharmaceuticals; American Regent; Arena; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cardiac Dimensions; Cardior; Cardurion; CellProThera; Cytokinetics; Eli Lilly; GlaxoSmithKline; Merck; Moderna; Myokardia; Novartis; Quantum Genomics; Roche Diagnostics Corporation; Sanofi Pasteur Inc.; Sarepta Therapeutics; Tenaya; Theracos; Tremeau
Received research grant from: Actelion Pharmaceuticals; Alnylam Pharmaceuticals; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Celladon Corporation; Cytokinetics; Eidos; Eli Lilly; GlaxoSmithKline; Ionis; Mesoblast; Myokardia; Neutronik; Novartis; Novo Nordisk; Respicardia Inc.; Sanofi Pasteur; Theracos; Us2.ai
Holds stock options in: DiNAQOR